BRPI0410249A - moléculas que melhoram a distribuição dérmica de vacinas contra influenza - Google Patents

moléculas que melhoram a distribuição dérmica de vacinas contra influenza

Info

Publication number
BRPI0410249A
BRPI0410249A BRPI0410249-5A BRPI0410249A BRPI0410249A BR PI0410249 A BRPI0410249 A BR PI0410249A BR PI0410249 A BRPI0410249 A BR PI0410249A BR PI0410249 A BRPI0410249 A BR PI0410249A
Authority
BR
Brazil
Prior art keywords
dermal
compartment
antigenic
epidermal
intradermal
Prior art date
Application number
BRPI0410249-5A
Other languages
English (en)
Inventor
Philippe Lauren
Robert Campbell
Ge Jiang
Vince Sullivan
Kevin Mar
Original Assignee
Becton Dickinson Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Becton Dickinson Co filed Critical Becton Dickinson Co
Publication of BRPI0410249A publication Critical patent/BRPI0410249A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"MOLéCULAS QUE MELHORAM A DISTRIBUIçãO DéRMICA DE VACINAS CONTRA INFLUENZA". A presente invenção está relacionada a formulações de vacinas dérmicas, criadas para distribuição direcionada de uma composição imunogênica a um compartimento dérmico da pele incluindo os compartimentos intradérmicos e epidérmicos. As formulações de vacinas dérmicas da invenção compreendem um agente antigênico ou imunogênico, e pelo menos uma molécula, por exemplo, um agente químico, que melhore a apresentação e/ou disponibilidade do agente antigênico ou imunogênico para as células imunológicas do compartimento intradérmico ou compartimento epidérmico resultando em uma resposta imunológica aumentada. As formulações de vacinas dérmicas da invenção têm eficácia aumentada à medida que o agente antigênico ou imunogênico é distribuido ao compartimento intradérmico ou compartimento epidérmico com melhorada apresentação e/ou disponibilidade para as células imunológicas que ali residem. A eficácia aumentada das formulações de vacinas dérmicas resulta em uma resposta imune terapeuticamente eficaz após uma única dose intradérmica ou epidérmica, com doses mais baixas de agente antigênico ou imunogênico do que as convencionalmente usadas, e sem a necessidade de imunizações reguladas.
BRPI0410249-5A 2003-05-12 2004-05-12 moléculas que melhoram a distribuição dérmica de vacinas contra influenza BRPI0410249A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47024303P 2003-05-12 2003-05-12
PCT/US2004/014755 WO2005016239A2 (en) 2003-05-12 2004-05-12 Molecules enhancing dermal delivery of influenza vaccines

Publications (1)

Publication Number Publication Date
BRPI0410249A true BRPI0410249A (pt) 2006-05-23

Family

ID=34193009

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410249-5A BRPI0410249A (pt) 2003-05-12 2004-05-12 moléculas que melhoram a distribuição dérmica de vacinas contra influenza

Country Status (8)

Country Link
US (1) US20050123550A1 (pt)
EP (1) EP1622573A4 (pt)
JP (1) JP2007525463A (pt)
CN (1) CN101115472A (pt)
AU (1) AU2004264816A1 (pt)
BR (1) BRPI0410249A (pt)
CA (1) CA2525228A1 (pt)
WO (1) WO2005016239A2 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39494E1 (en) * 1992-02-27 2007-02-27 Intervet Inc. Inactivated mycoplasma hyopneumoniae and uses therefor
US20060018877A1 (en) * 2001-06-29 2006-01-26 Mikszta John A Intradermal delivery of vacccines and therapeutic agents
EP1416986A4 (en) * 2001-06-29 2005-12-14 Becton Dickinson Co INTRADERMIC DISTRIBUTION OF VACCINES AND GENE THERAPEUTIC AGENTS VIA MICROCANNULE
US7588774B2 (en) 2003-05-12 2009-09-15 Becton, Dickinson And Company Molecules enhancing dermal delivery of influenza vaccines
EP2923711A1 (en) * 2004-11-03 2015-09-30 Novartis Vaccines and Diagnostics, Inc. Influenza vaccination
RU2007129840A (ru) * 2005-01-05 2009-02-20 Филадельфия Хелт Энд Эдьюкейшн Корпорейшн Д/Б/А Дрексел Юниверсити Колледж Оф Медисин (Us) Средства доставки, биологически активные вещества и вирусные вакцины
CA2552596A1 (en) * 2005-08-09 2007-02-09 Solvay Pharmaceuticals B.V. Methods and systems for determining mid-value titers
AU2007259329A1 (en) * 2006-05-12 2007-12-21 Farris, Darise Anthrax compositions and methods of use and production
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
HUE036180T2 (hu) 2006-09-26 2018-06-28 Infectious Disease Res Inst Szintetikus adjuvánst tartalmazó vakcina készítmény
WO2008139648A1 (ja) * 2007-05-15 2008-11-20 Hisamitsu Pharmaceutical Co., Inc. マイクロニードルのコーティング方法
US8506966B2 (en) 2008-02-22 2013-08-13 Novartis Ag Adjuvanted influenza vaccines for pediatric use
US9107815B2 (en) * 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
TWI351288B (en) * 2008-07-04 2011-11-01 Univ Nat Pingtung Sci & Tech Cpg dna adjuvant in avian vaccines
EP2358383A4 (en) * 2008-11-21 2011-11-23 Univ Miami HIV / SIV VACCINES FOR THE MANUFACTURE OF SLEEPAGE AND SYSTEM IMMUNITY
EP2396032B1 (en) 2009-02-10 2016-09-28 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
WO2010111586A2 (en) * 2009-03-27 2010-09-30 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Mucosal immunization
HUE031051T2 (en) * 2009-06-05 2017-06-28 Infectious Disease Res Inst Synthetic glycopyranosyl lipid adjuvant and vaccine compositions containing it
US9517205B2 (en) 2010-08-20 2016-12-13 Seqirus UK Limited Soluble needle arrays for delivery of influenza vaccines
BR112013027057A2 (pt) * 2011-04-21 2020-08-11 Trustees Of Tufts College composições e métodos para a estabilização de agentes ativos
SI2850431T1 (en) 2012-05-16 2018-08-31 Immune Design Corp. Vaccines for hsv-2
WO2014127155A2 (en) * 2013-02-15 2014-08-21 Samuel Bogoch Methods of identifying, preventing, and treating virulent hand foot and mouth disease virus using replikin sequences
EP2986303B1 (en) 2013-04-18 2020-02-26 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
WO2015042567A1 (en) * 2013-09-23 2015-03-26 Emory University Use of egfr pathway inhibitors to increase immune responses to antigens
BR112020011205A8 (pt) 2017-12-07 2023-02-07 Merck Sharp & Dohme Formulações de composições de vacina contra o vírus da dengue
CN109432419B (zh) * 2018-12-20 2022-04-22 天津瑞普生物技术股份有限公司 一种免疫佐剂、灭活疫苗及其制备方法
CN113966228A (zh) * 2019-06-11 2022-01-21 葛兰素史密斯克莱生物公司 黏膜疫苗配制剂
CN111420046B (zh) * 2020-05-27 2021-01-12 四川省畜牧科学研究院 一种动物疫苗佐剂及其制备方法
CN111840214B (zh) * 2020-08-21 2022-03-15 江苏省农业科学院 一种兽用疫苗的温敏型水凝胶佐剂、制备方法及其应用
CN117752633B (zh) * 2023-12-22 2024-06-07 善恩康生物科技（苏州）有限公司 一种高生物活性的益生菌微胶囊制剂
CN121313817A (zh) * 2025-12-09 2026-01-13 江苏华诺泰生物医药科技有限公司 一种含皂苷的疫苗佐剂及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1183629B (de) * 1962-12-21 1964-12-17 Behringwerke Ag Verfahren zur Stabilisierung biologisch aktiven Materials
JPH0688911B2 (ja) * 1985-06-06 1994-11-09 国立予防衛生研究所長 インフルエンザワクチン及びその製造方法
CA2054228A1 (en) * 1990-10-30 1992-05-01 Masaharu Oki Muramyldipeptide derivatives and influenza vaccine comprising the derivatives
US6485729B1 (en) * 1993-09-13 2002-11-26 Protein Sciences Corporation Neuraminidase-supplemented compositions
US5912000A (en) * 1994-09-23 1999-06-15 Zonagen, Inc. Chitosan induced immunopotentiation
US5702717A (en) * 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
GB9522351D0 (en) * 1995-11-01 1996-01-03 Medeva Holdings Bv Vaccine compositions
DK0885002T3 (da) * 1996-03-04 2011-08-22 Penn State Res Found Materialer og fremgangsmåder til forøgelse af cellulær internalisering
US5861174A (en) * 1996-07-12 1999-01-19 University Technology Corporation Temperature sensitive gel for sustained delivery of protein drugs
GB9725084D0 (en) * 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
AT408615B (de) * 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
ATE481108T1 (de) * 1999-02-26 2010-10-15 Novartis Vaccines & Diagnostic Verwendung von bioadhaesiven und adjuvantien für die mukosale anwendung von antigenen
US6494865B1 (en) * 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
ES2315244T3 (es) * 1999-11-12 2009-04-01 Fibrogen, Inc. Gelatina recombinante en vacunas.
JP2004509838A (ja) * 2000-04-28 2004-04-02 スプラテック　ファーマ　インコーポレイティド 樹状細胞の活性化誘導のための組成物および方法
AU2001276831A1 (en) * 2000-06-22 2002-01-02 Rxkinetix, Inc. Delivery vehicle composition and methods for delivering antigens and other drugs
WO2002000171A2 (en) * 2000-06-26 2002-01-03 Rxkinetix, Inc. Composition for delivery of hematopoietic growth factor
US20030092145A1 (en) * 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
NZ525076A (en) * 2000-10-02 2004-09-24 Glaxosmithkline Biolog S A split enveloped RSV virus vaccine fomulation
US20040071734A1 (en) * 2001-02-23 2004-04-15 Nathalie Garcon Novel vaccine
JP2004520144A (ja) * 2001-04-27 2004-07-08 グラクソスミスクライン　バイオロジカルズ　ソシエテ　アノニム 新規ワクチン
EP1572915A4 (en) * 2002-04-11 2011-01-05 Medimmune Vaccines Inc PRESERVATION OF BIOACTIVE MATERIALS BY SPRAY DRYING

Also Published As

Publication number Publication date
JP2007525463A (ja) 2007-09-06
US20050123550A1 (en) 2005-06-09
WO2005016239A2 (en) 2005-02-24
AU2004264816A1 (en) 2005-02-24
WO2005016239A3 (en) 2007-10-04
EP1622573A4 (en) 2008-09-10
EP1622573A2 (en) 2006-02-08
CN101115472A (zh) 2008-01-30
CA2525228A1 (en) 2005-02-24

Similar Documents

Publication Publication Date Title
BRPI0410249A (pt) moléculas que melhoram a distribuição dérmica de vacinas contra influenza
US9050293B2 (en) Small molecule solubilization system
JP5406531B2 (ja) 皮膚外用剤
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
WO2006060710A3 (en) Vaccine formulations for intradermal delivery comprising adjuvants and antigenic agents
BR112015021470A2 (pt) conjugado de polímero para administração de um agente bioativo
BR112018073676A2 (pt) lipossomas peguilados e métodos de uso
BR0210804A (pt) Vacinação de dose única com mycoplásma hyopneumoniae
BR112022017891A2 (pt) Métodos para tratar a infecção por coronavírus e lesão pulmonar induzida por inflamação resultante
BR112014028633A8 (pt) tratamento de amd usando sflt-1 de aav
BRPI0417225A (pt) métodos de aumentar a resposta imune no compartimento intradérmico e compostos úteis nos referidos métodos
WO2002041853A1 (en) O/w emulsion composition and method of preparing the same
BR112012007550A2 (pt) composição em gel, produtos de tratamento de verruga, e de calos/calosidade, método para tratar uma doença de pele, dispensador para administrar uma composição para tratar uma doença de pele em um indivíduo, e, método para aprimorar administração tópica de ácido salicílico a um indivíduo
BRPI0415986A (pt) método e aparelho para reduzir a incidência do uso de tabaco
RU2015122627A (ru) Кожные композиции, содержащие неприродные гигроскопические аминокислоты
JP2021091730A (ja) 多相組成物
BRPI0621599A8 (pt) vacina baseada em células b carregadas com o ligante da célula t exterminadora natural e antígeno
BR112019006350B8 (pt) Composição cosmética para cabelo, método para tratar o cabelo e método para conferir ao cabelo um ou mais efeitos de cuidado
BR112018008551A2 (pt) composição, e, métodos para umedecer, e proteger, reparar, ou restaurar a barreira lipídica da pele, para melhorar a oclusividade de uma formulação farmacêutica ou cosmética, para melhorar a umidificação da superfície da pele e para manter a eficiência de barreira da pele.
BR112015017903A2 (pt) vacina de subunidade de mycobacterium avium subsp. paratuberculosis única ou de múltiplos estágios
US20210301289A1 (en) Methods of treating osmidrosis
BR112021025545A2 (pt) Formulações de penetração transdérmica
BR112019009246A2 (pt) formulações de cosméticos para aplicações tópicas contendo moléculas derivadas de eritropoietina
BR112016012435A8 (pt) vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2
BR112017006599A2 (pt) composição farmacêutica de vacina para administração transdérmica

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.